Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Exelixis Reigns In Spending, It Looks To Offload Early-Stage Assets

This article was originally published in The Pink Sheet Daily

Executive Summary

Management elaborates on plans to scale down early discovery and drug development to focus resources on its three lead partnered drugs.

You may also be interested in...



Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results

In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.

Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results

In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.

Exelixis Stays The Course Under New Leadership of Michael Morrissey

As the R&D chief transitions to CEO, he sees no huge strategic shifts for Exelixis, though it "has had a tough six months."

Related Content

Topics

UsernamePublicRestriction

Register

PS070459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel